脂蛋白(a)与前蛋白转化酶枯草杆菌蛋白酶/kexin 9型抑制剂
Lipoprotein(a) and inhibitors of proprotein convertase subtilisin/kexin type 9.
作者信息
Kotani Kazuhiko, Banach Maciej
机构信息
Division of Community and Family Medicine, Jichi Medical University, Shimotsuke, Tochigi, Japan.
Department of Hypertension, Chair of Nephrology and Hypertension, Medical University of Lodz, Lodz, Poland.
出版信息
J Thorac Dis. 2017 Jan;9(1):E78-E82. doi: 10.21037/jtd.2017.01.40.
Abstract
Lipoprotein(a) [Lp(a)] has been identified as a risk factor for cardiovascular disease. Lp(a) levels are also high under certain clinical conditions, including familial hypercholesterolemia and high blood low-density lipoprotein (LDL) cholesterol levels. Few effective generic therapies for modulating Lp(a) have been developed. However, new therapies involving inhibitors of proprotein convertase subtilisin/kexin type 9 (PCSK9) using monoclonal antibodies have markedly reduced the blood LDL levels-and the Lp(a) levels as well. Much attention has therefore been focused on this therapy and its utility. The mechanism by which PCSK9 inhibitors reduce the Lp(a) levels remains unclear. We here describe the effects of PCSK9 inhibitors on Lp(a) and discuss potential mechanisms and perspectives of this topic.
摘要
脂蛋白(a)[Lp(a)]已被确定为心血管疾病的一个危险因素。在某些临床情况下，包括家族性高胆固醇血症和血液低密度脂蛋白(LDL)胆固醇水平升高时，Lp(a)水平也会升高。目前很少有有效的通用疗法来调节Lp(a)。然而，使用单克隆抗体的涉及前蛋白转化酶枯草杆菌蛋白酶/kexin 9型(PCSK9)抑制剂的新疗法显著降低了血液LDL水平，同时也降低了Lp(a)水平。因此，人们对这种疗法及其效用给予了极大关注。PCSK9抑制剂降低Lp(a)水平的机制尚不清楚。我们在此描述PCSK9抑制剂对Lp(a)的影响，并讨论该主题的潜在机制和前景。
相似文献
1
Lipoprotein(a) and inhibitors of proprotein convertase subtilisin/kexin type 9.脂蛋白(a)与前蛋白转化酶枯草杆菌蛋白酶/kexin 9型抑制剂
J Thorac Dis. 2017 Jan;9(1):E78-E82. doi: 10.21037/jtd.2017.01.40.
2
Apolipoprotein(a) phenotype determines the correlations of lipoprotein(a) and proprotein convertase subtilisin/kexin type 9 levels in patients with potential familial hypercholesterolemia.载脂蛋白(a)表型决定了潜在家族性高胆固醇血症患者脂蛋白(a)和前蛋白转化酶枯草溶菌素/克那霉 9 水平的相关性。
Atherosclerosis. 2018 Oct;277:477-482. doi: 10.1016/j.atherosclerosis.2018.08.011.
3
AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C Assessment with Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined with Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 trial.AMG145，一种针对前蛋白转化酶枯草溶菌素 9 的单克隆抗体，可显著降低接受他汀类药物治疗的高胆固醇血症患者的脂蛋白(a)：来自 LDL-C 评估与前蛋白转化酶枯草溶菌素 9 单克隆抗体抑制联合他汀类药物治疗（LAPLACE）-心肌梗死溶栓治疗（TIMI）57 试验的分析。
Circulation. 2013 Aug 27;128(9):962-9. doi: 10.1161/CIRCULATIONAHA.113.001969. Epub 2013 Jul 24.
4
Relationship between "LDL-C", estimated true LDL-C, apolipoprotein B-100, and PCSK9 levels following lipoprotein(a) lowering with an antisense oligonucleotide.载脂蛋白(a)降低后 LDL-C、估计真实 LDL-C、载脂蛋白 B-100 和 PCSK9 水平的关系。
采用反义寡核苷酸。
J Clin Lipidol. 2018 May-Jun;12(3):702-710. doi: 10.1016/j.jacl.2018.02.014. Epub 2018 Mar 1.
5
New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.新型 LDL 胆固醇降低治疗方法：药理学、临床试验及与急性冠脉综合征的相关性。
Clin Ther. 2013 Aug;35(8):1082-98. doi: 10.1016/j.clinthera.2013.06.019. Epub 2013 Aug 8.
6
Roles of the low density lipoprotein receptor and related receptors in inhibition of lipoprotein(a) internalization by proprotein convertase subtilisin/kexin type 9.低密度脂蛋白受体及相关受体在枯草杆菌蛋白酶/kexin 9型前蛋白转化酶抑制脂蛋白(a)内化中的作用
PLoS One. 2017 Jul 27;12(7):e0180869. doi: 10.1371/journal.pone.0180869. eCollection 2017.
7
Effects of PCSK9 Inhibition With Alirocumab on Lipoprotein Metabolism in Healthy Humans.阿利西尤单抗抑制前蛋白转化酶枯草溶菌素9对健康人类脂蛋白代谢的影响。
Circulation. 2017 Jan 24;135(4):352-362. doi: 10.1161/CIRCULATIONAHA.116.025253. Epub 2016 Dec 16.
8
Lipoprotein(a) in atherosclerotic cardiovascular disease and proprotein convertase subtilisin/kexin-type 9 inhibitors.载脂蛋白(a)在动脉粥样硬化性心血管疾病和前蛋白转化酶枯草溶菌素 9 抑制剂中的作用。
Clin Chim Acta. 2025 Jan 15;565:119982. doi: 10.1016/j.cca.2024.119982. Epub 2024 Oct 2.
9
Plasma lipoprotein-associated phospholipase A2 is inversely correlated with proprotein convertase subtilisin-kexin type 9.血浆脂蛋白相关磷脂酶 A2 与前蛋白转化酶枯草溶菌素 9 呈负相关。
Arch Med Res. 2012 Jan;43(1):11-4. doi: 10.1016/j.arcmed.2012.01.001. Epub 2012 Jan 31.
10
PCSK9 Inhibition with alirocumab increases the catabolism of lipoprotein(a) particles in statin-treated patients with elevated lipoprotein(a).阿利西尤单抗抑制 PCSK9 可增加他汀类药物治疗的脂蛋白(a)升高患者脂蛋白(a)颗粒的代谢。
Metabolism. 2020 Jun;107:154221. doi: 10.1016/j.metabol.2020.154221. Epub 2020 Mar 30.
引用本文的文献
1
Assessment of the trends in lipoprotein(a) concentration in high-risk cardiovascular patients: A retrospective study.高危心血管疾病患者脂蛋白(a)浓度趋势评估：一项回顾性研究。
Qatar Med J. 2025 Mar 5;2025(1):16. doi: 10.5339/qmj.2025.16. eCollection 2025.
2
Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute coronary syndrome: a systematic review and meta-analysis.急性冠状动脉综合征患者早期应用前蛋白转化酶枯草溶菌素 9（PCSK9）抑制剂：系统评价和荟萃分析。
BMC Cardiovasc Disord. 2024 Jul 30;24(1):395. doi: 10.1186/s12872-024-04057-w.
3
Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): from bench to bedside.靶向前蛋白转化酶枯草溶菌素 9（PCSK9）：从实验室到临床。
Signal Transduct Target Ther. 2024 Jan 8;9(1):13. doi: 10.1038/s41392-023-01690-3.
4
Insight into the Evolving Role of PCSK9.深入了解前蛋白转化酶枯草溶菌素9（PCSK9）不断演变的作用。
Metabolites. 2022 Mar 17;12(3):256. doi: 10.3390/metabo12030256.
5
Lipoprotein(a)-The Crossroads of Atherosclerosis, Atherothrombosis and Inflammation.脂蛋白(a)-动脉粥样硬化、动脉血栓形成和炎症的十字路口。
Biomolecules. 2021 Dec 24;12(1):26. doi: 10.3390/biom12010026.
6
Risk Assessment and Clinical Management of Children and Adolescents with Heterozygous Familial Hypercholesterolaemia. A Position Paper of the Associations of Preventive Pediatrics of Serbia, Mighty Medic and International Lipid Expert Panel.杂合子家族性高胆固醇血症儿童和青少年的风险评估与临床管理。塞尔维亚预防儿科学会、Mighty Medic及国际脂质专家小组的立场文件。
J Clin Med. 2021 Oct 25;10(21):4930. doi: 10.3390/jcm10214930.
7
Reducing Cardiac Injury during ST-Elevation Myocardial Infarction: A Reasoned Approach to a Multitarget Therapeutic Strategy.降低ST段抬高型心肌梗死期间的心脏损伤：多靶点治疗策略的合理方法
J Clin Med. 2021 Jul 1;10(13):2968. doi: 10.3390/jcm10132968.
8
Pleiotropic Effects of PCSK-9 Inhibitors.PCSK-9 抑制剂的多效性作用。
Int J Mol Sci. 2021 Mar 19;22(6):3144. doi: 10.3390/ijms22063144.
9
Effect of Evolocumab on Non-High-Density Lipoprotein Cholesterol, Apolipoprotein B, and Lipoprotein(a): A Pooled Analysis of Phase 2 and Phase 3 Studies.依洛尤单抗对非高密度脂蛋白胆固醇、载脂蛋白 B 和脂蛋白(a)的影响：2 期和 3 期研究的汇总分析。
J Am Heart Assoc. 2020 Mar 3;9(5):e014129. doi: 10.1161/JAHA.119.014129. Epub 2020 Mar 2.
10
Lipoprotein(a) the Insurgent: A New Insight into the Structure, Function, Metabolism, Pathogenicity, and Medications Affecting Lipoprotein(a) Molecule.脂蛋白(a)：反叛者——对脂蛋白(a)分子的结构、功能、代谢、致病性及相关药物的新见解
J Lipids. 2020 Feb 1;2020:3491764. doi: 10.1155/2020/3491764. eCollection 2020.
本文引用的文献
1
Lipoprotein Biomarkers and Risk of Cardiovascular Disease: A Laboratory Medicine Best Practices (LMBP) Systematic Review.脂蛋白生物标志物与心血管疾病风险：实验室医学最佳实践（LMBP）系统评价
J Appl Lab Med. 2016 Sep 1;1(2):214-229. doi: 10.1373/jalm.2016.021006. Epub 2016 Aug 1.
2
Statin non-adherence and residual cardiovascular risk: There is need for substantial improvement.他汀类药物治疗依从性不佳与心血管残留风险：仍需大幅改善。
Int J Cardiol. 2016 Dec 15;225:184-196. doi: 10.1016/j.ijcard.2016.09.075. Epub 2016 Sep 26.
3
Advances in the field of proprotein convertase subtilisin kexin type 9 inhibitors.前蛋白转化酶枯草溶菌素9型抑制剂领域的进展
Curr Opin Cardiol. 2016 Nov;31(6):644-653. doi: 10.1097/HCO.0000000000000332.
4
Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease.载脂蛋白 B 代谢途径抑制剂治疗杂合子型家族性高胆固醇血症或动脉粥样硬化性心血管疾病患者的成本效果分析。
JAMA. 2016 Aug 16;316(7):743-53. doi: 10.1001/jama.2016.11004.
5
PCSK9 inhibitors: monoclonal antibodies for the treatment of hypercholesterolemia.前蛋白转化酶枯草溶菌素9（PCSK9）抑制剂：用于治疗高胆固醇血症的单克隆抗体。
Drugs Today (Barc). 2016 Mar;52(3):183-92. doi: 10.1358/dot.2016.52.3.2440527.
6
Evidence-based assessment of lipoprotein(a) as a risk biomarker for cardiovascular diseases - Some answers and still many questions.基于证据的脂蛋白(a)作为心血管疾病风险生物标志物的评估——一些答案和许多仍待解决的问题。
Crit Rev Clin Lab Sci. 2016 Dec;53(6):370-8. doi: 10.1080/10408363.2016.1188055. Epub 2016 Jun 26.
7
Lipoprotein (a)-We Know So Much Yet Still Have Much to Learn ….脂蛋白(a)——我们知道很多，但仍有很多要学习……
J Am Heart Assoc. 2016 Apr 23;5(4):e003597. doi: 10.1161/JAHA.116.003597.
8
Lipoprotein(a) Interactions With Low-Density Lipoprotein Cholesterol and Other Cardiovascular Risk Factors in Premature Acute Coronary Syndrome (ACS).脂蛋白(a)在早发急性冠状动脉综合征（ACS）中与低密度脂蛋白胆固醇及其他心血管危险因素的相互作用
J Am Heart Assoc. 2016 Apr 23;5(4):e003012. doi: 10.1161/JAHA.115.003012.
9
Lipoprotein(a) Levels in Patients With Abdominal Aortic Aneurysm.腹主动脉瘤患者的脂蛋白(a)水平
Angiology. 2017 Feb;68(2):99-108. doi: 10.1177/0003319716637792. Epub 2016 Sep 29.
10
Lipoprotein(a) and Arterial Stiffness Parameters.脂蛋白(a)与动脉僵硬度参数。
Pulse (Basel). 2015 Sep;3(2):148-52. doi: 10.1159/000438733. Epub 2015 Aug 25.
Zotero 插件